In this review, we discuss the mutations and molecular diagnosis of tumours with hyperactivated mtor signalling, clinical trials of rapamycin analogues, the rationale behind second-generation non-rapamycin-analogue mtor inhibitors, and the ongoing early-phase clinical trials using these agents. The gene discussed is MTOR; the disease is neoplasm.